Home > Result Summaries: Compounds > adefovir

Result Summaries: adefovir

GSK Study ID	Phase	Title	Summary (Download)
103814	phase 4	An open label, multicenter phase IV study of adefovir dipivoxil in Korean patients with chronic hepatitis B (CHB) (0 citation(s))
105711	n\a	A post-marketing surveillance to monitor the safety of HEPSERA(adefovir dipivoxil 10mg) adminstered in Korean subjects according to the prescribing information (1 citation(s))
112299	phase 4	Drug Use Investigation for HEPSERA (adefovir) Tablet (0 citation(s))
200173	phase 4	Renal Safety of Adefovir Dipivoxil (ADV) in Chinese Patients with Chronic Hepatitis B (0 citation(s))
ADF104070	phase 4	An open label study of adefovir dipivoxil for the treatment of patients with chronic hepatitis B related advanced fibrosis or cirrhosis. (0 citation(s))
ADF105220	Phase 3	Phase III study of Adefovir Dipivoxil tablets in patients with compensated chronic hepatitis B -Comparative study against Lamivudine- (0 citation(s))
ADF106632	Phase 4	A 2-year multi-centre, open-label, local phase IV study to demonstrate the efficacy and safety of adefovir dipivoxil tablets (10mg) in Chinese subjects with HBe antigen negative Chronic Hepatitis B (0 citation(s))
ADF108005	phase 4	A phase IV, open label, single arm, multicenter, extension study of adefovir dipivoxil for Korean patients with chronic hepatitis B(CHB) who have completed ADF 103814 (0 citation(s))
ADF108356	Phase 4	A 48-week multi-centre, open-label, local phase IV study to demonstrate the efficacy and safety of adefovir dipivoxil tablets (10mg) in Chinese subjects with compensated Chronic Hepatitis B (0 citation(s))
ADF20001	Phase 4	Open label compassionate access programme to provide adefovir dipivoxil to patients with chronic hepatitis B infection. (0 citation(s))
ADF30001	Phase 3	A Multi-Centre, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total) Adefovir Dipivoxil Treatment. (Report on Year 1 and Year 2 Data) (6 citation(s))
ADF30001 (Year 1 to Year 4)	Phase 3	A Multi-Center, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for the Treatment of ChinesePatients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total) Adefovir Dipivoxil Treatment. (Report on data outto 4 years) (10 citation(s))
ADF30001_3	Phase 3	A Multi-Center, Double-Blind , Randomized, Placebo-Controlled Phase II/III Study of Adefovir Dipivoxil for theTreatment of Chinese Patients with HBeAg positive Chronic Hepatitis B Followed by Long-term (5 Years total)Adefovir Dipivoxil Treatment. (Report on interim data out to 3 years) (10 citation(s))
ADF30001_5	Phase 3	A multicentre double blind randomised placebo controlled phase II/III study of adefovir dipivoxil for the treatment of Chinese patients with HBeAg positive chronic hepatitis B. (12 citation(s))
ADF30002	Phase 3	Clinical Evaluation of Adefovir Dipivoxil [GW284873X] in Patients with chronic hepatitis B (including cirrhosis B) who have signs of clinical deterioration associated with the replication of YMDD variant HBV following lamivudine therapy (1 citation(s))
ADF30003	Phase 3	Clinical evaluation of adefovir dipivoxil (GW284873X) in patients with chronic hepatitis B (including cirrhosis B) who have signs of clinical deterioration associated with the replication of YMDD variant HBV following lamivudine therapy – A follow-up long-term study of ADF30002 (a 16-week, open ... (0 citation(s))